Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies

Giovanni Cigliana, Eleonora Torti, Francesca Gulli, Elena De Santis, Maria Teresa Dell'Abate, Luigi Colacicco, Francesco Pisani, Laura Conti, Umberto Basile

Research output: Contribution to journalArticle

Abstract

Background: Monoclonal gammopathies encompass a wide range of diseases characterized by the monoclonal expansion of a B-cell clone. Despite emerging therapeutic strategies, chances of survival of patients who are affected are still scarce, which implies that new tools are necessary not only for the diagnosis but also for the follow-up of patients affected by such diseases. In this context, the use of free light chains (FLCs) has been incorporated into many guidelines. Likewise, tumor microenvironment is consistently gaining importance as role player in tumor pathogenesis. Specifically, Syndecan-1 (CD138), a heparan-sulfate proteoglycan is attracting interests as it is highly expressed and shed by myeloma plasma-cells. The aim of our study was to analyze CD138 levels in the serum of patients affected by multiple myeloma or light chain only disease, and to compare the values obtained with free light chain (FLC) kappa, lambda and FLC ratio in both groups of patients. Methods: 84 patients affected by Multiple Myeloma and Light Chain Myeloma were recruited for this study. Serum CD138 was assessed by ELISA (Diaclone Research, France) and FLC values were quantified by nephelometry (Freelite TM Human Kappa and Lambda Free Kits, The Binding Site, UK). Data was analyzed by GraphPad Prism software and Statgraph. Results: We observed higher CD138 mean values in myeloma patients compared to the light chain only myeloma group. A positive linear regression of CD138 and FLC was observed in the light chain only cohort as opposed to myeloma patients which show an inverse trend. Conclusions: The study highlighted an existing relationship between FLCs and CD138 and wishes to seek also a correlation in order to rapidly and efficiently perform diagnosis and different diagnostic schemes.

Original languageEnglish
Article number37
JournalJournal of Experimental and Clinical Cancer Research
Volume34
Issue number1
DOIs
Publication statusPublished - Apr 23 2015

Fingerprint

Syndecan-1
Paraproteinemias
Light
Serum
Multiple Myeloma
Nephelometry and Turbidimetry
Heparan Sulfate Proteoglycans
Tumor Microenvironment
France
Linear Models
B-Lymphocytes
Software
Clone Cells
Enzyme-Linked Immunosorbent Assay
Binding Sites

Keywords

  • Free light chains
  • Multiple Myeloma
  • Syndecan I

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies. / Cigliana, Giovanni; Torti, Eleonora; Gulli, Francesca; De Santis, Elena; Dell'Abate, Maria Teresa; Colacicco, Luigi; Pisani, Francesco; Conti, Laura; Basile, Umberto.

In: Journal of Experimental and Clinical Cancer Research, Vol. 34, No. 1, 37, 23.04.2015.

Research output: Contribution to journalArticle

Cigliana, Giovanni ; Torti, Eleonora ; Gulli, Francesca ; De Santis, Elena ; Dell'Abate, Maria Teresa ; Colacicco, Luigi ; Pisani, Francesco ; Conti, Laura ; Basile, Umberto. / Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies. In: Journal of Experimental and Clinical Cancer Research. 2015 ; Vol. 34, No. 1.
@article{eca56df3233740409b4a444275a39824,
title = "Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies",
abstract = "Background: Monoclonal gammopathies encompass a wide range of diseases characterized by the monoclonal expansion of a B-cell clone. Despite emerging therapeutic strategies, chances of survival of patients who are affected are still scarce, which implies that new tools are necessary not only for the diagnosis but also for the follow-up of patients affected by such diseases. In this context, the use of free light chains (FLCs) has been incorporated into many guidelines. Likewise, tumor microenvironment is consistently gaining importance as role player in tumor pathogenesis. Specifically, Syndecan-1 (CD138), a heparan-sulfate proteoglycan is attracting interests as it is highly expressed and shed by myeloma plasma-cells. The aim of our study was to analyze CD138 levels in the serum of patients affected by multiple myeloma or light chain only disease, and to compare the values obtained with free light chain (FLC) kappa, lambda and FLC ratio in both groups of patients. Methods: 84 patients affected by Multiple Myeloma and Light Chain Myeloma were recruited for this study. Serum CD138 was assessed by ELISA (Diaclone Research, France) and FLC values were quantified by nephelometry (Freelite TM Human Kappa and Lambda Free Kits, The Binding Site, UK). Data was analyzed by GraphPad Prism software and Statgraph. Results: We observed higher CD138 mean values in myeloma patients compared to the light chain only myeloma group. A positive linear regression of CD138 and FLC was observed in the light chain only cohort as opposed to myeloma patients which show an inverse trend. Conclusions: The study highlighted an existing relationship between FLCs and CD138 and wishes to seek also a correlation in order to rapidly and efficiently perform diagnosis and different diagnostic schemes.",
keywords = "Free light chains, Multiple Myeloma, Syndecan I",
author = "Giovanni Cigliana and Eleonora Torti and Francesca Gulli and {De Santis}, Elena and Dell'Abate, {Maria Teresa} and Luigi Colacicco and Francesco Pisani and Laura Conti and Umberto Basile",
year = "2015",
month = "4",
day = "23",
doi = "10.1186/s13046-015-0155-4",
language = "English",
volume = "34",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies

AU - Cigliana, Giovanni

AU - Torti, Eleonora

AU - Gulli, Francesca

AU - De Santis, Elena

AU - Dell'Abate, Maria Teresa

AU - Colacicco, Luigi

AU - Pisani, Francesco

AU - Conti, Laura

AU - Basile, Umberto

PY - 2015/4/23

Y1 - 2015/4/23

N2 - Background: Monoclonal gammopathies encompass a wide range of diseases characterized by the monoclonal expansion of a B-cell clone. Despite emerging therapeutic strategies, chances of survival of patients who are affected are still scarce, which implies that new tools are necessary not only for the diagnosis but also for the follow-up of patients affected by such diseases. In this context, the use of free light chains (FLCs) has been incorporated into many guidelines. Likewise, tumor microenvironment is consistently gaining importance as role player in tumor pathogenesis. Specifically, Syndecan-1 (CD138), a heparan-sulfate proteoglycan is attracting interests as it is highly expressed and shed by myeloma plasma-cells. The aim of our study was to analyze CD138 levels in the serum of patients affected by multiple myeloma or light chain only disease, and to compare the values obtained with free light chain (FLC) kappa, lambda and FLC ratio in both groups of patients. Methods: 84 patients affected by Multiple Myeloma and Light Chain Myeloma were recruited for this study. Serum CD138 was assessed by ELISA (Diaclone Research, France) and FLC values were quantified by nephelometry (Freelite TM Human Kappa and Lambda Free Kits, The Binding Site, UK). Data was analyzed by GraphPad Prism software and Statgraph. Results: We observed higher CD138 mean values in myeloma patients compared to the light chain only myeloma group. A positive linear regression of CD138 and FLC was observed in the light chain only cohort as opposed to myeloma patients which show an inverse trend. Conclusions: The study highlighted an existing relationship between FLCs and CD138 and wishes to seek also a correlation in order to rapidly and efficiently perform diagnosis and different diagnostic schemes.

AB - Background: Monoclonal gammopathies encompass a wide range of diseases characterized by the monoclonal expansion of a B-cell clone. Despite emerging therapeutic strategies, chances of survival of patients who are affected are still scarce, which implies that new tools are necessary not only for the diagnosis but also for the follow-up of patients affected by such diseases. In this context, the use of free light chains (FLCs) has been incorporated into many guidelines. Likewise, tumor microenvironment is consistently gaining importance as role player in tumor pathogenesis. Specifically, Syndecan-1 (CD138), a heparan-sulfate proteoglycan is attracting interests as it is highly expressed and shed by myeloma plasma-cells. The aim of our study was to analyze CD138 levels in the serum of patients affected by multiple myeloma or light chain only disease, and to compare the values obtained with free light chain (FLC) kappa, lambda and FLC ratio in both groups of patients. Methods: 84 patients affected by Multiple Myeloma and Light Chain Myeloma were recruited for this study. Serum CD138 was assessed by ELISA (Diaclone Research, France) and FLC values were quantified by nephelometry (Freelite TM Human Kappa and Lambda Free Kits, The Binding Site, UK). Data was analyzed by GraphPad Prism software and Statgraph. Results: We observed higher CD138 mean values in myeloma patients compared to the light chain only myeloma group. A positive linear regression of CD138 and FLC was observed in the light chain only cohort as opposed to myeloma patients which show an inverse trend. Conclusions: The study highlighted an existing relationship between FLCs and CD138 and wishes to seek also a correlation in order to rapidly and efficiently perform diagnosis and different diagnostic schemes.

KW - Free light chains

KW - Multiple Myeloma

KW - Syndecan I

UR - http://www.scopus.com/inward/record.url?scp=84936875486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936875486&partnerID=8YFLogxK

U2 - 10.1186/s13046-015-0155-4

DO - 10.1186/s13046-015-0155-4

M3 - Article

AN - SCOPUS:84936875486

VL - 34

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 37

ER -